Twitter

Chordate Medical presents year-end report for 2022 in web conference on February 28th

Chordate Medical publishes its year-end report for 2022 on Tuesday, February 28, 2023, at 08:30 CET. On the same day, at 14:00 CET, CEO Anders Weilandt will present the report during a web conference. The conference is followed by a Q&A session. You can follow the conference via computer or mobile devices.

To register for the web conference, register via the following link: https://attendee.gotowebinar.com/register/3690216538735029342

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company’s website www.chordate.com and on Västra Hamnen Corporate Finance’s YouTube channel.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter